Cytogen (US) begins OncoScint breast cancer trials
This article was originally published in Clinica
Cytogen (US) has begun clinical trials of its OncoScint CR/OV imaging agent for use in pre-operative breast cancer staging. The only FDA-approved monoclonal antibody-based tumour imaging agent, OncoScint CR/OV is indicated for colorectal and ovarian cancer. The multi-centre breast cancer trial aims to confirm the agent's ability to detect axillary lymph node metastases. In a 20-patient study at the Italian National Cancer Institute in Milan, the agent had a sensitivity of 91% in detecting axillary lymph node involvement in mastectomy candidates.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.